Skip to main content

Alzheimer's

Celia

Leeftijd icoon
50 - 80 years
Diagnose icoon
Mild to moderate Alzheimer’s disease
Duratie onderzoek
Approximately 2 years
Locatie icoon
Amsterdam

About this research

In order to participate in this study, you must be able to speak and read Dutch fluently. 

The goal of this study is to evaluate how safe and effective the new drug BIIB080 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug BIIB080 with the effect of a placebo (a drug without an active ingredient, a ‘fake drug’). The study drug is injected into the back.

Alzheimer’s is a type of dementia in which abnormal proteins, called tau, accumulate in the brain and damage nerve cells. BIIB080 is intended to block tau from forming by reducing the RNA (a molecule in the body which tells the body what proteins to form) which is responsible for the tau protein. It is hoped that this will help to treat Alzheimer’s disease.

You and your study partner, someone who knows you well and can answer questions about your daily functioning, will visit the research center approximately 17 times, during approximately 2 years. In addition, you will also have 8 check-ups via telephone. The duration of a visit is not always the same because not every visit has the same procedures. Some of these visits may last 6 hours, others 3.5 hours. A phone call takes around 15 minutes. The research takes place in Amsterdam.

This study is commissioned by Biogen.

How does the application process go?

You always decide whether you participate in a study. Participation is always voluntary.

  1. You apply via the online form, this is non-binding.
  2. After application, you are phoned, this is also an opportunity for you to ask questions. During this conversation, we also ask some questions to see whether you are eligible to participate in research. After this conversation, you determine whether you want to progress to step 3.
  3. You receive an email with the request to sign a document in which you give permission to retrieve your medical data.
  4. When your medical data shows that you meet the requirements to participate in the study, you are invited to a meeting at our location. During this meeting, you receive information and have the opportunity to ask questions, before you decide to participate in research.
  5. If you decide to participate in the study, you sign a form and will start the study within several weeks.

What are the benefits of Brain Research Center?

  1. You always come first – everything we do revolves around you.
  2. Experienced team of doctors, neuropsychologists, and nurses.
  3. Open and homely atmosphere – this will make you feel relaxed and right at home.
  4. Clarity – expert in medicine research which is why you will be well informed during all steps of the process and can always come to us for questions.
  5. Always nearby – 3 locations spread through the Netherlands.

What's in it for me?

  • You may experience benefits from a new treatment.
  • You will be monitored by a specialized team of healthcare professionals. They can give you advice and monitor whether there is a change in your daily functioning.
  • You make a meaningful contribution to a future without Alzheimer’s.
  • You contribute to the advancement of science.

Can I participate?

You can participate when:

  • You have a mild to moderate stage Alzheimer’s disease
  • You are between 50 and 80 years old
  • You have someone close to you/a caregiver who can accompany you during the visits to the research center and can answer questions about your health and functioning, among other things.

Are you unsure whether you meet these requirements? Then you can always apply. We will then check together whether you are suitable to participate. 

Take action against Alzheimer’s. Sign up to participate.

Latest Alzheimer’s trials

Efavirenz
Efavirenz

Efavirenz

The goal of this study is to evaluate how safe and effective the drug efavirenz is for the treatment of participants with early stage Alzheimer’s disease. The study compares the effect of the drug efavirenz with the effect of a placebo (a drug without an active ingredient, a ‘fake drug’).

audience55 - 75 years

levelEarly stage of Alzheimer's

durationApproximately 18 weeks

locationAmsterdam

Polaris AD
Polaris AD

Polaris AD

The goal of this study is to evaluate how safe and effective the new drug PRI-002 is for the treatment of participants with MCI or a mild form of dementia caused by Alzheimer’s disease. The study compares the effect of the new drug PRI-002 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is a capsule that is taken orally.

audience55 - 90 years

levelEarly Alzheimer’s disease (MCI or mild AD

duration1 to 2 years

locationAmsterdam, Den Bosch or Zwolle

PRImus AD
PRImus AD

PRImus AD

The goal of this study is to evaluate how safe and effective the new drug PRI-002 is for the treatment of participants with MCI or a mild form of dementia caused by Alzheimer’s disease. The study compares the effect of the new drug PRI-002 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is a capsule that is taken orally.

audience55 - 80 years

levelMCI or a mild form of dementia caused by Alzheimer’s disease

durationApproximately 1 to 2 years

locationAmsterdam, Den Bosch or Zwolle